Login to Your Account



Price Set at $93K

FDA Clears Provenge; Up Next: Fast Launch, Slow Ramp

By Trista Morrison


Friday, April 30, 2010
Dendreon Corp. made history on Thursday, securing a long sought-after FDA approval for prostate cancer vaccine Provenge (sipuleucel-T). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription